19:54 , May 25, 2018 |  BioCentury  |  Emerging Company Profile

Universal ambitions

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development. Emergex launched in 2016 with IP...
23:53 , Feb 22, 2018 |  BC Innovations  |  Product R&D

Shooting for the universe

CureVac AG is bringing a new modality to the race for a universal flu vaccine with an mRNA program backed by a grant from the Bill & Melinda Gates Foundation. While the company believes its...
23:29 , Oct 6, 2017 |  BioCentury  |  Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
20:19 , Sep 22, 2017 |  BC Week In Review  |  Financial News

BiondVax prices $10M follow-on

Flu vaccine company BiondVax Pharmaceuticals Ltd. (Tel Aviv:BVXV; NASDAQ:BVXV) raised $10 million through the sale of 1.7 million American Depositary Shares (ADS) at $6 in a follow-on underwritten by Joseph Gunnar. Each ADS represents 40...
22:01 , Jan 5, 2017 |  BC Week In Review  |  Financial News

BiondVax completes private placement

BiondVax raised NIS10.9 million ($2.8 million) through the sale of 33.8 million shares at NIS0.32 in a private placement with Angels High Tech Investments. BiondVax Pharmaceuticals Ltd. (Tel Aviv:BVXV; NASDAQ:BVXV), Ness Ziona, Israel ...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Completed Phase IIb enrollment

BiondVax completed enrollment of 224 volunteers in a double-blind, Hungarian Phase IIb trial comparing intramuscular M-001 plus H5N1 influenza vaccine vs. H5N1 influenza vaccine alone. BiondVax Pharmaceuticals Ltd. (Tel Aviv:BVXV; NASDAQ:BVXV), Ness Ziona, Israel  ...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Additional Phase II data

An analysis of blood plasma samples from 120 elderly volunteers aged 65 and older who were treated 3 years ago in the double-blind, Israeli Phase II BVX-005 trial showed that >=50% of subjects who received...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Multimeric-001 Universal Flu Vaccine: Preliminary Phase II data

Preliminary data from the double-blind, placebo-controlled, Israeli Phase II BVX-006 trial in 36 volunteers ages 50-65 showed that 3 intramuscular injections of 1 mg M-001 every 21 days followed by an injection of the 2014/2015...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Tiers, some fears

3Q15 Financial Markets Preview With biotech more than six years into a bull run, most of the sector's bankers and buysiders remain comfortable in uncharted waters because generalists are not jumping ship en masse in...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Financial News

BiondVax financial update

BiondVax Pharmaceuticals Ltd. (Tel Aviv:BVXV; NASDAQ:BVXV), Ness Ziona, Israel   Business: Infectious   Date announced: 2015-06-24   Note: BiondVax raised $550,000 through the sale of 110,000 ADSs at $5 to cover the overallotment from its...